Articles

1. When Patient Diversity Informs Formulation: Reimagining Treatment for Seborrheic Dermatitis

   • Meredith Tyree Polaskey
   • Heather Woolery-Llloyd
   • Raj Chovatiya

   Commentary Open access 27 April 2024

   

2. Safety and Effectiveness of Percutaneous Ultrasound-Guided Galvanic Current in Tunnels of Patients with Hidradenitis Suppurativa: A Pilot Study

   • Alberto Soto-Moreno
   • Carlos Cuenca-Barrales
   • Alejandro Molina-Leyva

   Original Research Open access 27 April 2024

   

3. Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review

   • Joseph Joseph
   • Kelvin Truong
   • Annika Smith

   Brief Report Open access 25 April 2024

   

4. Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom

   • Evangeline J. Pierce
   • Russel T. Burge
   • Yunni Yi

   Original Research Open access 23 April 2024

   

5. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

   • Alexander Egeberg
   • Jason E. Hawkes
   • April Armstrong

   Original Research Open access 22 April 2024 Pages: 1007 - 1018

   

6. Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO

   • Elisabeth Riedl
   • Andreas Pinter
   • Christopher Schuster

   Brief Report Open access 22 April 2024

   

7. The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016

   • Sissel Brandt Toft Sørensen
   • Prethibha George
   • Vera Ehrenstein

   Original Research Open access 16 April 2024 Pages: 993 - 1006

   

8. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

   • Tiago Torres
   • Anne Sohrt Petersen
   • José Manuel Carrascosa

   Original Research Open access 13 April 2024 Pages: 983 - 992

   

9. Novel Topical Treatments for Itch

   • Rami H. Mahmoud
   • Omar Mahmoud
   • Gil Yosipovitch

   Review Open access 13 April 2024 Pages: 829 - 840

   

10. Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study

    • Michela Starace
    • Francesca Pampaloni
    • Zoe Apalla

    Original Research Open access 10 April 2024 Pages: 953 - 970

11. Letter to the Editor Regarding: Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study

    • Ruiyao Hu
    • Yue Wang
    • Chen Li

    Letter Open access 09 April 2024 Pages: 1063 - 1065

12. Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities

    • Luca Potestio
    • Nello Tommasino
    • Matteo Megna

    Review Open access 09 April 2024 Pages: 841 - 852

13. Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry

    • Eric L. Simpson
    • Ben Lockshin
    • Andrew Korotzer

    Publisher Correction Open access 09 April 2024

    

14. Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”

    • A. David Burden

    Letter Open access 05 April 2024 Pages: 1067 - 1069

15. Clinical Characteristics and Therapeutic Aspects of Blaschko Linear Psoriasis

    • Ling Chen
    • Yufan Cheng
    • Zhu Shen

    Brief Report Open access 05 April 2024 Pages: 1039 - 1048

    

16. Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis

    • Tina Bhutani
    • John Koo
    • J. Gabriel Vasquez

    Brief Report Open access 04 April 2024 Pages: 1019 - 1025

    

17. Acute Systemic Toxicity Caused by Topical Application of EMLA Cream on a Leg Ulcer: Case Report and Review of Literature

    • Sarah Marie Hoffmann
    • Anna Luisa Hartmann
    • Christoph Mathis Schempp

    Case Report Open access 03 April 2024 Pages: 1057 - 1062

    

18. Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment

    • Manuel Pacareu Francès
    • Laura Vila-Vecilla
    • Gustavo Torres de Souza

    Original Research Open access 31 March 2024 Pages: 971 - 981

    

19. Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis

    • Lawrence F. Eichenfield
    • Linda F. Stein Gold
    • Juliana M. Canosa

    Original Research Open access 28 March 2024 Pages: 875 - 892

    

20. Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study

    • Ying Li
    • Chengzhi Lv
    • Yuling Shi

    Original Research Open access 27 March 2024 Pages: 907 - 918

    

21. Virtual Learning Decreases the Carbon Footprint of Medical Education

    • Divya Sharma
    • Julianne Rizzo
    • Jenny E. Murase

    Original Research Open access 26 March 2024 Pages: 853 - 859

22. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

    • April Armstrong
    • Alvaro González-Cantero
    • Andrew Blauvelt

    Original Research Open access 23 March 2024 Pages: 933 - 952

    

23. Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance

    • Brent R. Moody
    • Aaron S. Farberg
    • Walton A. Taylor

    Original Research Open access 23 March 2024 Pages: 861 - 873

    

24. Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries

    • Sergio Vañó-Galván
    • Alexander Egeberg
    • Anthony Bewley

    Brief Report Open access 21 March 2024 Pages: 1027 - 1037

    

25. Effect of Makeup Use on Depressive Symptoms: An Open, Randomized and Controlled Trial

    • Marcos C. Veçoso
    • Souvenir Zalla
    • Vânia R. Leite-Silva

    Original Research Open access 21 March 2024 Pages: 777 - 791

    

26. Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

    • Luigi Gargiulo
    • Luciano Ibba
    • Alessandra Narcisi

    Original Research Open access 21 March 2024 Pages: 919 - 932

27. Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials

    • Alexander Egeberg
    • Curdin Conrad
    • Diamant Thaçi

    Original Research Open access 15 March 2024 Pages: 745 - 758

    

28. Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD)

    • Sonja Molin
    • Lotte Seiding Larsen
    • Marie L. A. Schuttelaar

    Original Research Open access 15 March 2024 Pages: 643 - 669

    

29. Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment

    • Chun-Xia He
    • Chao Wu
    • Hong-Zhong Jin

    Original Research Open access 14 March 2024 Pages: 893 - 906

    

30. Atypical Fibroxanthoma Treated with a Topical Combination of Imiquimod, Tazarotene, and 5-Fluorouracil

    • William J. Nahm
    • Evangelos V. Badiavas
    • John Shen

    Case Report Open access 12 March 2024 Pages: 1049 - 1056

    

31. Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives

    • Lawrence F. Eichenfield
    • Jinan Liu
    • Peter Anderson

    Original Research Open access 08 March 2024 Pages: 685 - 696

    

32. Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα

    • Julia Tittes
    • Jennifer Brell
    • Johannes Stöckl

    Original Research Open access 08 March 2024 Pages: 613 - 626

    

33. Burden of Topical Treatments in Psoriasis and Preferred Criteria of Choice: A Survey-Based Evaluation of Patients in Europe

    • Anthony Bewley
    • Lauren Hiribarne
    • Sicily Mburu

    Original Research Open access 08 March 2024

    

34. A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State

    • Tom M. Hillary
    • Tine Vanhoutvin
    • Séverine Vermeire

    Original Research Open access 07 March 2024 Pages: 767 - 775

    

35. The Need of Differential Diagnosis Between Vulvar Lichen Sclerosus and Autoimmune Dermatoses in Adolescent Girls

    • Agnieszka Dulska
    • Jakub Bodziony
    • Agnieszka Drosdzol-Cop

    Original Research Open access 07 March 2024 Pages: 759 - 766

36. Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials

    • Rui Sun
    • Mercedes Bustamante
    • Victor Dong

    Original Research Open access 07 March 2024 Pages: 729 - 743

    

37. The Role of the Gut-Joint Axis in the Care of Psoriatic Arthritis: A Two-Sample Bidirectional Mendelian Randomization Study

    • Yihong Gan
    • Jingqun Liu
    • Yongsheng Fan

    Original Research Open access 07 March 2024 Pages: 713 - 728

    

38. The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing

    • Yuling Shi
    • Edward Lain
    • Aline Stennevin

    Original Research Open access 07 March 2024 Pages: 697 - 712

    

39. Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”

    • Kim Rand
    • Juan Manuel Ramos-Goñi
    • José-Carlos Armario-Hita

    Letter Open access 05 March 2024 Pages: 823 - 827

    

40. Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib

    • Axel De Greef
    • Ghita Benjelloun
    • Marie Baeck

    Case Report Open access 05 March 2024 Pages: 813 - 817

    

41. Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US

    • Alvan Cheng
    • Xinqing Deng
    • Boni E. Elewski

    Original Research Open access 05 March 2024 Pages: 627 - 641

    

42. Botulinum Toxin A and B for Palmoplantar Hyperhidrosis

    • Trond Eilertsen
    • Bjørn Øivind Kvammen
    • Øystein Grimstad

    Brief Report Open access 01 March 2024 Pages: 805 - 811

    

43. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

    • Ashley Wysong
    • Ally‐Khan Somani
    • Sarah T. Arron

    Original Research Open access 01 March 2024 Pages: 593 - 612

    

44. Herpes Zoster Recurrence: A Narrative Review of the Literature

    • Raunak Parikh
    • O’Mareen Spence
    • Iain Kaan

    Review Open access 28 February 2024 Pages: 569 - 592

    

45. Insights into Early Systemic Treatment in Atopic Dermatitis: Scientific Facts and Practical Considerations

    • Efstratios Vakirlis
    • Stamatios Gregoriou
    • Eleni Sotiriou

    Commentary Open access 27 February 2024 Pages: 563 - 568

46. Readability of Patient Electronic Materials for Atopic Dermatitis in 23 Languages: Analysis and Implications for Dermatologists

    • Tomasz Skrzypczak
    • Anna Skrzypczak
    • Jacek C. Szepietowski

    Original Research Open access 24 February 2024 Pages: 671 - 684

    

47. Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

    • Valerie J. Ludbrook
    • David C. Budd
    • Wei Jing Loo

    Original Research Open access 19 February 2024 Pages: 489 - 504

    

48. Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’

    • Mike Bastian
    • Nick Freemantle
    • Patricia Guyot

    Letter Open access 16 February 2024 Pages: 819 - 821

49. Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence

    • Tina Bhutani
    • Aaron S. Farberg

    Review Open access 16 February 2024 Pages: 341 - 360

    

50. Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience

    • Sascha Gerdes
    • Anna Campanati
    • Elizabeth Lazaridou

    Brief Report Open access 15 February 2024 Pages: 793 - 804